Radiopharmaceuticals Market Predicted to Garner $10.3 Bn by 2032; At a CAGR of 8.85% | Market.us Report
April 19, 2023 16:32 ET
|
Market.Us
New York, April 19, 2023 (GLOBE NEWSWIRE) -- The Radiopharmaceuticals market recorded a valuation of USD 4.5 billion in 2022 and is expected to reach USD 10.3 billion by the end of 2032, expanding...
Radiopharmaceuticals Market to Observe Prominent Growth of USD 12.18 Billion by 2030, Size, Share, Trends, Demand, Growth and Competitive Analysis
March 22, 2023 08:14 ET
|
Data Bridge Market Research
NEW YORK, March 22, 2023 (GLOBE NEWSWIRE) -- A recent study report released by Data Bridge Market research titled “Radiopharmaceuticals Market” (covering USA, Europe, China, Japan, India, South East...
Radiopharmaceuticals Market to Hit USD 10.26 Billion by 2030 due to Increasing Prevalence of Cancer and Cardiovascular Diseases Worldwide
March 17, 2023 10:07 ET
|
SNS Insider pvt ltd
Pune, March 17, 2023 (GLOBE NEWSWIRE) -- The size for Radiopharmaceuticals Market was valued at USD 5.07 billion in 2022 and is projected to reach USD 10.26 billion by 2030, with a Compound Annual...
QSAM Biosciences Completes Enrollment of Initial Cohort in its Phase 1 Study of CycloSam® Targeting Metastatic Bone Cancer
February 28, 2023 08:00 ET
|
QSAM Biosciences Inc.
Austin, TX, Feb. 28, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...
QSAM Biosciences Provides 2022 Update and 2023 Milestones to Shareholders
January 10, 2023 07:00 ET
|
QSAM Biosciences Inc.
AUSTIN, Texas, Jan. 10, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...
Nusano Announces Appointment of Chris Lowe as Chief Executive Officer
December 13, 2022 10:00 ET
|
Nusano
VALENCIA, Calif. and WEST VALLEY CITY, Utah, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Nusano, Inc., a company reshaping the production of cancer-fighting radioisotopes, today announced Chris Lowe as the...
During the Forecast Period Ranging from 2022-32, Global Radiopharmaceuticals Market Uptake is Anticipated to Flourish at a Value CAGR of 4.3% to Reach US$ 9.5 Bn | Future Market Insights, Inc.
October 26, 2022 09:30 ET
|
Future Market Insights Global and Consulting Pvt. Ltd.
NEWARK, Del, Oct. 26, 2022 (GLOBE NEWSWIRE) -- NEWARK, Del: The global radiopharmaceuticals market stands at US$ 6.2 Bn as of now and is expected to reach US$ 9.5 Bn by the year 2032 at a CAGR of...
QSAM Biosciences Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 17, 2022 08:00 ET
|
QSAM Biosciences Inc.
Dosed First Patient in Phase 1 Clinical Program Evaluating CycloSam® Radiopharmaceutical Drug Candidate for Treatment of Metastatic Bone Cancer Austin, TX, May 17, 2022 (GLOBE NEWSWIRE) -- QSAM...
Telix Radiopharmaceutical Production Facility Buildout Commences
March 21, 2022 18:41 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and BRUSSELS, Belgium, March 22, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to provide a material update on the development...
QSAM Biosciences Appoints Adriann Sax to Board of Directors
January 25, 2022 08:30 ET
|
QSAM Biosciences Inc.
Austin, TX, Jan. 25, 2022 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...